MAPK9 and breast cancer: In contrast, sensitivity to PAB was predicted by a 8-protein panel (Fig. 6N and O, Mann Whitney U-test, ***p < 0.001) with increased ERα (**p = 0.003), HER2 (**p = 0.003), CDK2-pThr160 (**p = 0.004), E-Cadherin-pSer838/840 (*p = 0.014), Cyclin D1, c-Raf-p259, JNK/SAPK-pThr183/Tyr185 and p38MAPK-pThr180/Tyr182 signals in responder BC-PDMs.